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Background: Chronic HIV infection commonly affects both cognition and mental health, even with excellent systemic
viral control. The causes of compromised brain health are likely to be a multi-factorial combination of HIV-related
biological factors, co-morbidities such as aging and cerebrovascular disease, and the erosion of coping skills, physical
health, and social supports resulting from the strains of living with a chronic illness.
Methods/design: This study aims to provide a better understanding of the relationship between cognitive complaints,
depression, and objectively measured cognitive impairment in HIV, and of the key factors, whether biological or
personal, which relate to these presentations and to their evolution over time. Characterization of this heterogeneity
will permit more focused pathophysiological studies, and allow more targeted interventions. The project makes
extensive use of Web-based research and health care delivery tools, aiming to provide cost-effective, “clinic ready” tools
to improve brain health in HIV. This project has two overarching aims, reflecting our dual goals of understanding and
improving brain health in HIV, focusing on cognitive impairment, its contributors and consequences.
The objectives are to contribute evidence for the validity of a brief brain health assessment, to estimate the extent to
which HIV-related cognition-relevant clinical factors and patient-centered outcomes inter-relate and evolve over time,
allowing identification of the mechanisms underpinning longitudinal change in brain health and to contribute
evidence for the feasibility, effectiveness potential, acceptability, and underlying mechanisms of promising
interventions for optimizing brain health. We adopt a cohort multiple randomized control trials design. A total of 900
participants will be characterized prospectively over a 27-month period to answer questions about the evolution of
outcomes of interest. All participants will be offered basic brain health self-management information. Sub-groups will
participate in pilot studies of specific, more intensive interventions to provide pragmatic evidence for feasibility,
effectiveness, and comparative effectiveness.
Discussion: This work will provide needed estimates of the burden, heterogeneity, evolution, and mechanisms
underlying compromised brain health in HIV, and test a range of promising non-pharmacological interventions. This is
an on-going study; the trials nested within this cohort that are currently recruiting participants were registered on 7
October 2015 (Clinicaltrials.gov NCT02571504 and NCT02571595).
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People living with HIV worry about their memory, with
good reason. As their life expectancies increase, it is be-
coming clear that both cognition and mental health can
be affected, even with excellent systemic viral control. Al-
though we are only beginning to understand these emer-
ging co-morbidities, they are likely the result of multiple
interacting processes. Various mechanisms have been pro-
posed, directly or indirectly related to HIV. HIV infects
cells within the central nervous system (CNS), highly ac-
tive anti-retroviral therapy (HAART) varies in its CNS
penetrance, providing a potential reservoir for viral repli-
cation, and local or systemic inflammation may affect
brain function [1, 2]. Antiretrovirals may themselves be
neurotoxic [3–5], and common co-morbidities such as
cerebrovascular disease, substance abuse and hepatitis C
infection can take their own toll on brain function. Finally,
the experience of living with chronic infection can
threaten brain health by affecting stress levels, coping,
physical health, and social supports. Mood disorders can
affect cognition even in otherwise healthy individuals [6],
and in HIV specifically, self-reported cognitive concerns
have been associated with depressive symptoms [7]. It
may be that depressive symptoms and cognitive difficulties
are two facets of brain dysfunction, or that depression af-
fects cognitive performance through effects on attention
or motivation [8]. This project acknowledges the potential
inter-relationship between cognition and mood in HIV,
addressing these together within a holistic framework of
brain health.
Although the burden of poor brain health in HIV in
Canada is unknown, it is likely to be high. Recent studies in
other developed countries, using comprehensive neuro-
psychological assessment, report a prevalence of (primarily
mild) HIV-associated neurocognitive disorders (HAND) of
30–50 % [9, 10]. Even higher rates have been documented
in those over the age of 50, a rapidly expanding group at
the frontier of existing knowledge about the combined ef-
fects of aging and longstanding HIV infection [11]. Depres-
sion is also common in HIV infection, with population-
based prevalence of major depressive disorder estimated as
high as 36 % [12]. Impaired cognition and depression,
whether together or separately, strike patients in their pro-
ductive years, and can affect medication adherence, occupa-
tional and social function, quality of life, and even
accelerate mortality [4, 13–18]. Progress in understanding
the heterogeneous, multi-factorial nature of compromised
brain health in HIV requires careful clinical
characterization, including of its evolution over time,
accompanied by hypothesis-driven research focused on
specific clinical phenotypes. Progress in predicting, treating
and mitigating the impact of poor brain health requires bet-
ter, practical clinical tools and evidence-based interventions
specifically tailored for people living with HIV.The nomenclature describing cognitive impairment, and
the modalities used to measure cognition vary across clin-
ical disciplines, hindering interdisciplinary research. Here,
we have chosen to use the term cognitive deficit and its
positive opposite, cognitive ability; we also distinguish be-
tween directly measured cognitive deficits (i.e. neuro-
psychological tests) and perceived cognitive deficits
reported as symptoms (here measured using validated
questionnaires). This method is broadly consistent with
the requirements of the current diagnostic criteria for
HAND [3]. Our view of cognition departs from current
categorical diagnosis, focusing instead on cognitive ability
as a “quantity” [19]. We propose that declines in cognitive
ability compared to the individual’s own baseline will be
the most useful trigger for intervention, and that stability
or improvements are likely to be more important to the
patient than whether they meet strict diagnostic thresh-
olds. Rigid use of diagnostic categories may prevent recog-
nition of real difficulties, and limit access to useful
interventions for patients with high (but deteriorating)
cognitive abilities [20, 21].
Current approaches to diagnosis of HAND rely on
neuropsychological testing [3]. This is resource-intensive,
with restricted availability. Front-line health care providers
who must judge whom and when to refer are poorly
equipped to respond to patients’ concerns about cognition:
What symptoms signal difficulties that warrant further in-
vestigation or intervention? What interventions are appro-
priate? Are there patients who do not report symptoms
who nonetheless have deficits and would benefit from as-
sessment and treatment? We recognize that a key challenge
in this area is to understand the link between what patients
are saying, which is what matters to them, and what the ob-
jective tests indicate. Further, we need to better understand
the relationship between different facets of brain
health, address these within an interdisciplinary frame-
work, and characterize their evolution over time. De-
veloping better ways to measure both symptoms and
signs that are feasible in everyday practice and tuned to
the full range of abilities in this population is a crucial
first step.
While better measurement and thorough description of
the clinical phenomenology and its temporal evolution are
necessary, they are not sufficient. People with HIV cannot
afford to wait for researchers to fully understand the mul-
tiple factors that are likely to underpin the brain health
challenges they are facing now. Research on the effects of
exercise, self-management and cognitive training in
healthy aging and mild cognitive impairment (MCI) shows
promise in improving cognitive functions that are also
commonly affected in HIV [22]. There is more than a con-
ceptual parallel between these conditions. Subtle patho-
logical aging changes are found in the brains of people
with HIV [23]. We hypothesize that non-pharmacological
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will make a difference in mood, cognitive performance,
and real world outcomes such as occupational func-
tioning and quality of life in HIV. Here we describe
the objectives, protocol and analytic plan for a project
addressing key questions related to brain health in
HIV using a cohort multiple randomized controlled
trials design.
Objectives
This project has three overarching aims reflecting the
core goals of identifying, understanding and optimizing
brain health in people living with HIV, focusing on cog-
nitive ability, its measurement, contributors and conse-
quences. The specific objectives are:
(i) To estimate the extent to which HIV-related clinical
factors and patient-centered outcomes relevant to
brain health and its consequences inter-relate and
evolve over time and to explore the mechanisms
underpinning longitudinal change in brain health;
(ii)To contribute evidence for the validity of a brief
brain health assessment approach combining both
patient-reported and measured cognitive deficits;
(iii)To contribute evidence for the feasibility,
effectiveness potential, and acceptability of
promising non-pharmacological interventions for
optimizing brain health.Fig. 1 Overview of research platform, including the main cohort, followed
multiple randomized controlled trials of non-pharmacological interventionsThis is an on-going study, with external funding from a
competitively awarded, peer-reviewed Team Grant from
the Canadian Institutes of Health Research (TCO-
125272), and institutional research ethics approval (Bio-




We have developed a platform to fully characterize the
heterogeneity of brain health in people with HIV, includ-
ing its evolution over time and its impact. This platform
also allows a sampling strategy, based on cohort multiple
randomized controlled trials design [24], to identify people
eligible for entering pilot studies of promising interven-
tions. Biological specimens (serum, plasma, peripheral
blood mononuclear cells, saliva for genetic analysis) are
banked in anticipation of future research, including novel
collaborations. The project overview is provided in Fig. 1.
Study population
The target population is people in middle age and older,
the group felt to be most at risk of both longer-term ef-
fects of HIV infection and the interaction between these
and aging-related brain changes: Inclusion criteria are
age ≥35, HIV+ for at least 1 year, able to communicate ad-
equately in either French or English, and able to give writ-
ten informed consent. If necessary, we will oversamplelongitudinally, and the strategy for sampling from this cohort for
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of each are enrolled. The focus is on milder cognitive defi-
cits, which is the area of greatest clinical uncertainty.
Thus, exclusion criteria include dementia (MoCA <18)
[25], or treating physician’s concern about capacity to con-
sent, life expectancy of <3 years or other personal factor
limiting the ability to participate in follow-up, non-HIV-
related neurological disorder likely to affect cognition,
known active CNS opportunistic infection or hepatitis C
requiring Interferon-based treatment during the follow-up
period, psychotic disorder, or current substance use dis-
order or severe substance use disorder within the past
12 months. Individuals with current or past major depres-
sive disorder are eligible for the core project, and indeed
will be the focus of one of the studies under our third aim.
There are additional inclusion/exclusion criteria for indi-
vidual sub-studies, described below. A brief questionnaire
is used to identify characteristics of all persons approached
for recruitment to determine whether non-participation
introduces a selection bias into our study.
The core of the research program is the development
and follow-up of a comprehensively characterized cohort
of persons with HIV. The cohort is being assembled
through consecutive sampling from five clinics in several
large cities in Canada: Montreal, Toronto, Hamilton, and
Vancouver. These clinics collectively manage thousands of
patients, with diverse demographic and HIV risk profiles,
most of whom are routinely followed at 3 month intervals.
A total of 900 participants will be comprehensively
assessed and followed longitudinally at 9 month intervals
over a 3 year period (four assessments).
Measurement strategy: the brain health platform
We will apply a theory-based measurement framework,
the Wilson-Cleary outcome model, to structure this por-
tion of the study (Fig. 2). This model is widely used to as-
sess the life impact of medical conditions. The model
comprehensively considers the relationship between char-
acteristics of the individual, and of their environment, as
they relate to a continuum from biological variables, to
symptoms, to functional status and quality of life [26].
There have been three studies using the Wilson-Cleary
model in HIV, with a restricted set of variables, and noneFig. 2 Wilson-Cleary outcome model. Characteristics of the individual inclu
environment include psychological and social supportsincluding cognitive constructs [26–28]. Figure 2 and
Table 1 present the constructs measured in the current
study in all patients within the Wilson-Cleary framework.
We have situated the brain health measures within the
‘symptom’ and ‘function’ rubrics of this model. Informa-
tion on the key constructs is collected through chart re-
view, face-to-face interviewing and direct testing, and
through questionnaires. All questionnaires are brief and
well known in the health literature, and widely tested in
various populations, permitting comparisons across health
conditions. To assure wide application to the broader clin-
ical context, we selected measures that are in the public
domain and available in English and French. The platform
will serve as a sampling frame for a series of trials target-
ing brain health in selected sub-groups.
Primary outcome: cognitive ability
Measurement of cognitive ability using the B-CAM©
(Brief Cognitive Ability Measure) is central to the plat-
form. This computerized test battery was developed using
Rasch Measurement Theory and Rasch analysis. Items
from cognitive tests and self-report cognitive difficulties
were co-calibrated to identify those that provided a meas-
ure of cognitive ability with linearized units so that the
total score can legitimately be used mathematically to
compare people on the same metric and to monitor
change [29, 30]. Including both objective tests and self-
report items is advantageous for eventual translation to
routine clinical practice, in that self-report information is
readily acquired and could be used to identify people in
need of more in-depth assessment. The B-CAM takes less
than 30 min to complete.
Self-report Cognitive Concerns will be measured using
the Perceived Deficit Questionnaire (PDQ) [31]. This 20-
item questionnaire (scored 0 to 80) measures cognitive
lapses, with a score >40 indicating cognitive impairment.
The PDQ has been used in several health conditions and
healthy populations [32, 33].
Cognitive reference standard
The neuropsychological battery recently developed for
CIHR Canadian HIV Trials Network (CTN) studies, the
CTN Neurocognitive Battery, will serve as the referencede motivation, symptom amplification; characteristics of the
Table 1 Constructs to be measured within the structure of the Wilson-Cleary framework
Characteristics of the individual
Age, sex, self-declared race, height, weight, education, work status, occupation, living situation, cognitive reserve indicators, coping, smoking, alcohol,
drug use, healthy eating behaviour
Biological and physiological
variables




Nadir CD4+, current immunological
markers, current viral load, peak
viral load, current ARV treatment,








pain, sleep quality, HIV related
signs and symptoms
Measured and self-reported cognitive









Physical activity; physical function;
self-efficacy for managing HIV
health challenges
Role participation: work status, work
quality, nature and frequency of
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battery allows diagnosis of HAND as per the 2007 defin-
ition [3] by testing at least five cognitive domains with at
least two tests per domain, while being as brief as pos-
sible. The tests are listed in Table 2 and take approxi-
mately 90 min to complete. In addition to diagnostic
and feasibility considerations, tests were chosen to be
available in both English and French with norms suitable
for use in Canada.
Multiple randomized controlled trials design
All participants are provided with an information pack-










aWechsler Adult Intelligence Scale-IV (WAIS-IV)
bWechsler Memory Scale-III (WMS-III)
cDelis-Kaplan Executive Function System (D-KEFS)brain health. Our Brain Health Now Tips cover recom-
mendations for stopping smoking, challenging the mind,
limiting alcohol and street drugs, increasing physical ac-
tivity, sleeping well, managing stress and negative
moods, healthy eating, and the importance of telling the
medical team about all current medications. In addition
to this, a series of pilot interventions targeting one or
more aspects of brain health are included in this study
(Table 3). Each trial has its own protocol, submitted for
separate ethical review. People who meet eligibility cri-
teria are identified from the database and those from the
site where the study is conducted will be offered the
intervention; eligible participants from the other sitesls Network (CTN) Neurocognitive Battery
Tasks
Hopkins Verbal Learning Test-Revised (HVLT-R)
Brief Visuospatial Memory Test-Revised (BVMT-R)
Tower of London
Stroop







Grooved Pegboard, dominant and non-dominant hand
Toni-IV
Table 3 Planned pilot trials for the brain health now study
Intervention Site Selection criteria [outcome measure]
B-CAM levela including a self-report cognitive
concern [B-CAM primary/secondary]
Other criterion
Cognitive training Montreal a[Primary]
Insomnia intervention All a[Secondary] Sleep dissatisfaction
Exercise Montreal [Primary] Sedentary; physical function limitations
Sleep apnea intervention Selected [Primary] Sleep dissatisfaction / sleep apnea screen
Goal management training Selected a[Primary]
Cognitive behavioural therapy Montreal [Secondary] Depressive symptoms
Relaxation Montreal [Secondary] Anxiety
aindicates that selection criteria include a score lower than the mean on the B-CAM
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and the insomnia intervention, have started recruitment.
For all but two of the trials, cognitive ability is the pri-
mary outcome. The trials are designed to have a com-
mon outcome definition (responder status), analysis and
sample size.Data collection
A research assistant (RA) is responsible for recruitment at
each of the study sites. The list of patients to be seen each
day is pre-screened to identify those ineligible. Eligible pa-
tients are invited to meet with the RA who explains the
study. In an observational study, it is essential to establish
the extent to which the sample is representative of the tar-
get population, by collecting key information about those
who decline participation, in order to understand the po-
tential for selection bias. Therefore, those unwilling to
enter the study are asked to provide a reason and respond
to two questions about cognitive concerns, both of which
are items from the B-CAM, and indicate age and whether
they are currently working.
Those who agree to enter the study provide written, in-
formed consent (see below). Participants next respond to
the questionnaire measures directly on a clinic-based
computer, guided and overseen by the study research as-
sistant as needed, and then, if they wish, complete them at
home. Data collection uses the Dacima Clinical Suite ver-
sion 3 (Dacima Software Inc.) electronic data capture
(EDC) software platform. The EDC platform allows data
to be entered into a secure, web-based database that com-
plies with regulatory requirement (FDA 21 CFR Part 11)
through any browser. The software includes a complete
audit trail, subject and data entry status tracking, real-time
data validation checks, dashboards/reporting and data ex-
traction functionalities. Data capture takes about 90 min
at the first visit, and 60 min at follow-up. Site RAs assist
with the administration of the B-CAM, ensure question-
naire measures are completed, and enter demographicand medical information, including standard of care blood
test results abstracted from computerized clinical data-
bases, anthropomorphic measures, patient report and
chart review into the web-based data management system.
The B-CAM is carried out on a separate Internet-based
platform (Inquisit, Millisecond Software), and merged
with the other data for further analysis.Statistical methods and sample size
Aim 1: To estimate the extent to which HIV-related clinical
factors and patient-centered outcomes relevant to brain
health and its consequences inter-relate and evolve over time
and to explore the mechanisms underpinning longitudinal
change in brain health
The analysis will estimate the complex relationships be-
tween cognitive ability, other indicators of brain health,
other symptoms, such as pain, functions in everyday life,
health-perception, and quality of life (QOL). We will trace
the connections between biological variables, objective
measures of cognition, and the constructs that really mat-
ter to patients (such as perceived health, which predicts
longevity [34, 35], and QOL–the reasons for living), using
the Wilson-Cleary model. The advantage of this approach
is that the antecedents, correlates, and consequences of
brain health can be fully described, leading to a better un-
derstanding of how to optimize function, perceived health,
and QOL in the presence of lower cognitive ability.
Structural Equation Modeling (SEM), one of a family of
related, sophisticated, multivariate statistical procedures,
will be used to test how well the Wilson-Cleary theoretical
model conforms to the data. SEM consists of two basic el-
ements: a measurement model, analyzed by factor ana-
lysis, and a structural model, using path analysis. SEM
uses latent variables to represent the constructs of interest,
recognizing that complex constructs are not adequately
represented by any one single measure, and thus the com-
monality between related measures is a better representa-
tion [36]. This method will permit the direct and indirect
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broader context of HIV morbidity, co-morbidities and life
impact of HIV infection.
Sample size for SEM is large: optimally 15 to 20 people
per parameter estimated. The number of parameters esti-
mated in a complex model can be substantial (approxi-
mately three per included latent variable) therefore sample
sizes in the range of 400 to 600 are needed for the
Wilson-Cleary model. Given the focus on cognition, it will
be informative to identify if the structure and relationships
between and among variables differ in the presence of
lower cognitive ability. As we are expecting about 40 % to
have some cognitive deficit, a sample size of 900 would
yield about 360 persons for an SEM model. The model
will also be fit longitudinally, providing the opportunity to
understand how changes in key constructs affect brain
health and function over time.
To address heterogeneity of the HIV population in terms
of evolution of cognitive ability over time, and co-evolution
of cognitive ability with antecedent variables, correlates and
consequences, a form of latent trajectory analysis (group-
based trajectory analysis; GBTA) [37] will be used. This
analysis is optimized with four or more time points. This
approach has been used to characterize evolution of cogni-
tive impairment over time in an elderly population [38, 39],
and apathy in a stroke population [38]5. GBTA assumes the
population is made up a mix of people with different longi-
tudinal trajectories and uses a semi-parametric approach to
group like with like. The optimal number and shape of tra-
jectories is determined by theory, Bayesian Information Cri-
teria (BIC), magnitude of the average posterior probability
of group assignment (with ≥0.70 recommended), and close-
ness of the theoretical and assigned proportions of people
to trajectories [37].
The sample sizes projected for this study should yield
up to 5 to 7 distinct trajectories [40], providing a detailed
view of the heterogeneity of longitudinal change and of
factors contributing to trajectory of change. Additional
multivariate approaches may be warranted, such as mixed
models, to assess the impact of key variables on longitu-
dinal change in brain health.
Aim 2. To contribute evidence for the validity of a brief
brain health assessment approach (B-CAM)
The strength of the relationship between the results of the
reference standard cognitive assessment and the B-CAM
will be tested using rank correlation and sensitivity and
specificity. To formally estimate the sensitivity and specifi-
city of B-CAM, we will use the classical method of Begg
and Greens [41], which assesses diagnostic tests when
there are different verification probabilities. Because the
new measure, B-CAM, is mapped to a standard normal
distribution (on a logit scale), it is possible to use the dis-
tribution to identify a cut-point for further testing.Validation will take place on the first 500 consecutive per-
sons enrolled. The sample size for this estimation is based
on the formula provided by Begg and Greens for sensitiv-
ity, specificity and corresponding 95 % confidence inter-
vals (CI). Assuming that approximately 40 % of people
will score in a range indicative of cognitive deficit on B-
CAM, we will recruit 100 % of all those with B-CAM evi-
dence of deficit (500 * 0.4 = 200) plus 20 % of the remain-
der (300 * 0.2 = 60). With this verification strategy, and
under the assumptions above, the estimated sensitivity is
0.86 (95 % CI: 0.73 to 0.93). The corresponding values for
specificity are 0.93 (95 % CI: 0.89 to 0.96). We will also es-
timate the effect of covariate status (age, co-infection with
hepatitis C, history of drug use, recent immigrant, or low
education) on sensitivity and specificity.
Aim 3: to contribute evidence for the feasibility,
effectiveness potential, and acceptability of interventions
holding promise for optimizing brain health
The analysis for all of the intervention trial cohorts is a mix
of within- and among-cohort contrasts including contrasts
with those eligible for selection, but not selected, who can
serve as controls. We have designed these pilots to identify
the proportion with a cognitive response rather than calcu-
lating an average response and comparing averages over
time or between cohorts. This responder-status analysis
provides more relevant information both at a group level
and at an individual level. As the time frames for each pilot
may be different, the definition of a responder can reflect
these differences. For example, responder-status could be
defined immediately post-intervention or at follow-up or
both. With a simple responder-status analysis, it is possible
to calculate the probability of achieving a certain responder
proportion, which will be useful for designing future trials.
For between-group comparisons, logistic regression will
be the global approach to analysis with responder-status
(yes-no, defined the same way for intervention and control
cohorts) as outcome. The exposure is cohort: intervention
vs. control. The control group is likely much larger than
the intervention cohorts, so comparing each cohort to the
control is statistically reasonable. People may not
complete all of a given intervention, which may affect op-
portunity for change; a restricted analysis will be con-
ducted on those completing at least 60 % of the sessions,
recognizing that power is reduced but the information
nonetheless valuable for the design of future studies.
Generalized estimating equations (GEE) will also be ap-
plied as a secondary, more general approach that permits
other time points to be modeled, and consideration of
other outcomes. This accommodates either binary (re-
sponder status) or continuous (scores on cognitive tests)
outcomes. This analysis uses a regression model, but clus-
tering of outcomes within time is controlled. For binary
outcomes, the effect of group (intervention or control) is
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parameter is an effect size equivalent to an adjusted
paired-t-test. An interaction term tests whether the effect
differed by group (i.e. was larger in the intervention group,
as hypothesized).
Additional analyses will be used to explain changes in
cognitive status as a function of changes expected from
the intervention. As the intervention cohorts are small, we
will use concordance parameters, rather than a regression
model, to quantify the degree to which changes in hypoth-
esized mechanisms by which the interventions operate
(improving exercise capacity, physical activity, healthy liv-
ing) are concordant (at the individual level) with changes
in the outcomes (cognitive ability or self-efficacy for self-
management).
There were two considerations in estimating sample
size. First, for the GEE analysis, a minimum sample size of
30 has been suggested [42, 43]. Second, the probability of
achieving a specific response proportion can be estimated
using the normal approximation to the binomial distribu-
tion when response proportions are not extreme (http://
stattrek.com/online-calculator/binomial.aspx). Assuming
that, in the absence of intervention, there is only a small
probability of making a positive cognitive response, say
10 % (p = 0.10), then with 30 subjects, the probability of
observing seven or more responders is unlikely, p < 0.03.
For other outcomes (depression and anxiety) which may
have a higher probability of positive response in the ab-
sence of intervention, say 20 %, then 11 or more re-
sponders out of 30 would need to be observed to be less
likely than 0.05 to have occurred by chance.
Ethics, consent and permissions
The project was approved by Research Ethics Board of
each of the participating institutions, with the caveat that
the pilot trials would each have their own protocol and
ethics submission. All participants provide written, in-
formed consent at the time of enrollment in the cohort.
Where deemed ethically permissible, we also collect lim-
ited information from eligible individuals who refuse par-
ticipation in the study in order to estimate selection bias.
The local research ethics board at one center did not ap-
prove the collection of information from refusers. For the
intervention studies that are recruited through telephone
or email contact and are delivered only through the Inter-
net, no additional visit is needed. We obtained ethics ap-
proval for these intervention studies only from the center
from which the study was going to be conducted, after
confirmation that this approach was in compliance with
the national regulatory framework in Canada.
The informed consent document stipulated that any
clinical results of importance for the participant’s medical
care would be provided to their physician. Most blood
tests are clinically indicated and are reviewed as part ofroutine care. For the information collected on the ques-
tionnaires, in collaboration with the site principal investi-
gators, we developed a list of “red flags” to identify
participants who may be in serious distress. The “red
flags” pertain to issues of mood, pain and quality of life, as
those were considered important to medical care. On a
monthly basis, answers to selected questions are extracted
from the database and the participants’ physicians are
alerted to the presence of worrisome self-reports.Discussion
This novel design, cohort multiple randomized controlled
trials, uses the strength of a large, epidemiologically de-
signed, observational study to provide a representative
sample that can be characterized prospectively to answer
questions about the evolution of outcomes of interest. In
addition, sub-groups of the sample are identified for
whom pilot testing of specific personalized interventions
would provide pragmatic evidence for feasibility, effective-
ness, and acceptability to patients. The study will also
provide a powerful platform for validating novel measure-
ment approaches and estimates of the burden and hetero-
geneity of cognitive deficits over time, and will support
hypothesis-driven research on mechanisms.
The findings from this work will be rigorous and the ex-
tent of their generalizability can be estimated. We expect
the results will apply to similar populations cared for in
specialized HIV clinics in Canada and the developed world
more generally, at least. We believe this whole person ap-
proach to brain health, emphasizing evolution over time,
and testing non-pharmacological interventions, will yield
both conceptual advances and practical, clinically-relevant
information applicable in the day-to-day management of
brain health in HIV. We anticipate making this rich data-
set publically available at the completion of the study, fol-
lowing publication of the primary research findings.
This study is also an example of interdisciplinary and
multi-site team science, enabled by funding from the
Canadian Institutes of Health Research that was ear-
marked to promote the development of new teams to ad-
dress emerging co-morbidities in HIV. We have included
community partners as part of our team. They have been
involved from the beginning, endorsing the relevance of
addressing cognitive concerns. These individuals have also
been invaluable for informing methods of data collection
and championing the study in the community.
Chronic HIV infection poses complex challenges that are
likely exacerbated by aging and the accrual of co-
morbidities, and likely affect brain health through multiple
paths. This project takes a multi-pronged approach to
measuring cognition and mental health concerns, under-
standing the basis of differences in cognitive ability, and
assessing potential interventions. We apply a novel
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design. Since a pivotal paper on this method was published
in 2009 [24], only a handful of studies have proposed this
design [44–48]. This will be the first study to use this de-
sign to test multiple interventions.
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